Aplastic anaemia treatment: the options and how they are chosen

Treatment exists, and the choice is rarely a single one

Aplastic anaemia (spelled "anemia" in the US) is rare, serious and treatable. The bone marrow stops making enough blood cells, and the aim of treatment is either to calm the immune attack that caused it or to replace the marrow altogether. Which route is right depends on the person, and on a few facts that the haematology team will establish early.

This page is the overview. It explains the three main approaches, how age, severity and donor availability steer the decision, what response looks like over time, and what can go wrong later. If you are still getting to grips with the condition itself, what aplastic anaemia is is the place to start, and each treatment below has its own page with more detail.

One note on tone. Aplastic anaemia is managed in specialist centres, and the decisions are made together with the patient. Nothing here replaces that conversation, and a list of things worth asking is gathered in questions to ask your haematologist.

Supportive care comes first, and it never really stops

Whatever else is planned, everyone with significant marrow failure gets supportive care. NHS inform describes the general approach as looking for specific causes, stopping any medicines that might have contributed, providing supportive care to treat symptoms and reduce the risk of bleeding and infection, and then considering definitive treatment with immunosuppression or a stem cell transplant (NHS inform).

In practice that means red cell and platelet transfusions when counts fall low, and medicines to prevent infection. For people with severe or very severe disease, NHS inform notes that these measures are likely to be ongoing. The British Society for Haematology guideline makes the same point more strongly: transfusion support, antimicrobial prophylaxis and prompt management of opportunistic infections remain key throughout the disease course (British Society for Haematology guideline).

The details of how transfusions are given, why iron can build up, and how infections are avoided are covered in blood and platelet transfusions. For some people with non-severe disease, supportive care may be the whole plan for a while. NHS inform lists "watch and wait", also called careful monitoring, as an option for those who do not need active treatment.

The three main approaches at a glance

For severe and very severe disease, supportive care is joined by one of two definitive treatments, or by a stem cell transplant from a different kind of donor. The table sets them side by side. It is a simplification, because real decisions weigh many more details.

Immunosuppressive therapy: calming the attack on the marrow

In most people, aplastic anaemia is caused by the immune system attacking the stem cells in the bone marrow. The NHLBI describes this as the most common cause of marrow damage, a type of autoimmune illness (NHLBI). Immunosuppressive therapy, often shortened to IST, tries to switch that attack off so the marrow can recover.

The standard combination is anti-thymocyte globulin (ATG), made from horses, with ciclosporin. NHS inform explains that ATG works against T cells, the part of the immune system that targets the marrow in this condition, and that ciclosporin is a tablet people will usually need to keep taking for about a year. It also mentions eltrombopag, a medicine that stimulates stem cell and platelet production, as something some patients are offered.

The evidence for adding eltrombopag is strong. The RACE trial, run by the European Society for Blood and Marrow Transplantation across 24 sites in six European countries, randomly assigned 197 previously untreated patients to horse ATG and ciclosporin with or without eltrombopag. The authors concluded that adding it improved the rate, rapidity and strength of blood count response without additional toxic effects. Event-free survival at two years rose from 34% to 46%, although overall survival was not significantly different, partly because patients who did not respond could be rescued with other treatment (Peffault de Latour et al., New England Journal of Medicine).

The same paper notes that, overall, about two thirds of patients respond to standard horse ATG plus ciclosporin. That is a good result, and it also means a third do not, which is why a second plan matters. The full picture, including side effects and what monitoring involves, sits on the immunosuppressive therapy page.

Stem cell transplant from a sibling donor

A stem cell transplant replaces the failing marrow with healthy donor marrow. The NHLBI says blood and bone marrow transplants may cure aplastic anaemia in some people. For a young person with a matched sibling, many specialists regard it as the treatment of choice. A review of clinical management from Johns Hopkins puts it plainly: transplantation is the treatment of choice for young patients who have a matched sibling donor (DeZern and Brodsky, Expert Review of Hematology).

The current British guideline words it a little differently. It describes the standard first-line options for newly diagnosed acquired severe or very severe disease as horse ATG and ciclosporin-based immunosuppression with eltrombopag, or a transplant from a matched sibling donor. Both are listed side by side, and age, severity by the Camitta criteria, and whether a compatible donor exists are named as the determinants of the decision.

The older review adds an advantage that is easy to overlook. Transplant reduces both the risk of relapse and the evolution of late clonal disorders, compared with immunosuppression alone. It also reported that in a large European analysis of 2,479 people with severe disease, 10-year survival was 73% for those transplanted first and 68% for those treated with immunosuppression first. Those figures come from older cohorts, so treat them as a guide to the shape of the comparison rather than a forecast. The process itself, from conditioning to recovery, is explained in stem cell transplant for aplastic anaemia.

Unrelated donors and the role of registers

Only a minority of people have a matched brother or sister. For the rest, a donor may be found through a register of volunteers. The British guideline says that an unrelated donor transplant in adults should be considered after lack of response to immunosuppression, and up front for young adults with severe infections and a readily available matched unrelated donor.

In other words, the usual order for adults is immunosuppression first, with an unrelated donor held as the next step. The exceptions are specific. Children and young adults are often handled differently, and the treating team can explain where a given patient fits.

The people on those registers matter more than most patients realise. Becoming a stem cell donor explains how to join a register and what donating involves.

How age, severity and donor availability shape the choice

Three questions do most of the work. How severe is the disease, how old and fit is the person, and is there a matched donor close at hand? NHS inform lists severity, age, general health and any underlying conditions as the things that tailor treatment, and says the choice between transplant and immunosuppression depends on age, health and whether a stem cell donor is available.

Roughly speaking, the younger the patient and the more severe the disease, the stronger the case for an early transplant when a sibling match exists. Older adults, or those with other health problems, usually do better with immunosuppression because transplant is harder to tolerate. Non-severe disease may need nothing more than monitoring and transfusions.

The guideline also asks for something that does not feature in most patient leaflets: because aplastic anaemia is so rare and so complex, it strongly recommends discussion in multidisciplinary meetings and involvement of expert centres. If you are being treated somewhere that sees only a few cases a year, asking about a specialist opinion is reasonable and common.

Response, relapse and what happens over time

Blood counts do not recover overnight. Trials like RACE check response at three and six months after starting treatment, which gives a sense of the clock: weeks of waiting, then months before anyone can say how well it has worked. Many people stay on transfusions for a good while in the meantime. A response might be partial, with counts that rise enough to stop transfusions, or complete, with counts in the normal range.

Setbacks can happen later. Relapse means the counts fall again after a response, and clonal evolution means that abnormal blood cell populations appear over time. The NHLBI warns that aplastic anaemia can raise the risk of complications including leukaemia or other serious blood conditions. The Johns Hopkins review names late clonal disorders such as myelodysplastic syndrome (MDS) and paroxysmal nocturnal haemoglobinuria (PNH) as risks after immunosuppression. In the large European comparison it cites, secondary malignancy occurred in 1.2% of those treated with immunosuppression alone and 0.1% of those transplanted.

For these reasons, follow-up does not end when the counts recover. The NHLBI notes that doctors monitor the condition and screen regularly for blood conditions, and that people on immune-suppressing medicine need to take steps to prevent infection and have annual flu shots.

Clinical trials and the future

NHS inform says plainly that research on treatments is ongoing, and the NHLBI site links to clinical trials for anaemia on its own pages. Trials have already reshaped practice: the use of eltrombopag alongside standard immunosuppression began with a single-group phase 1 to 2 study, which the randomised RACE trial then tested head to head.

Joining a trial is a personal decision with real pros and cons. It can give access to newer approaches, and it also means following a protocol. Ask the haematology team which studies are open, whether you are eligible, and what taking part would change about your care.

The takeaway for anyone starting out

Treatment for aplastic anaemia has two layers. Supportive care protects you while the marrow is failing, and definitive treatment, either immunosuppression or a transplant, aims to restore it. For younger patients with a matched sibling, transplant is a leading option. For many others, horse ATG, ciclosporin and eltrombopag is the standard route, with an unrelated donor transplant held in reserve.

No single path suits everyone, and the best one is the one your team chooses with you after weighing your age, the severity of the disease and the donors available. A later page may look at the practical side of recovery and everyday life, but the first step is simply understanding the options, and you now have the outline.